ALCLS Fundamental Analysis - CELLECTIS

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ALCLS. ALCLS was compared to 72 industry peers in the Biotechnology industry. While ALCLS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ALCLS is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALCLS had negative earnings in the past year.

In the past year ALCLS had a positive cash flow from operations.

ALCLS had negative earnings in each of the past 5 years.

ALCLS had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -14.12%, ALCLS is in the better half of the industry, outperforming 62.69% of the companies in the same industry.

ALCLS has a Return On Equity (-41.34%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-14.12%
ROE	-41.34%
ROIC	N/A

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALCLS has a Gross Margin of 4.64%. This is comparable to the rest of the industry: ALCLS outperforms 47.76% of its industry peers.

The Profit Margin and Operating Margin are not available for ALCLS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	4.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALCLS has been increased compared to 1 year ago.

ALCLS has more shares outstanding than it did 5 years ago.

ALCLS has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.80, we must say that ALCLS is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -0.80, ALCLS perfoms like the industry average, outperforming 46.27% of the companies in the same industry.

ALCLS has a debt to FCF ratio of 4.88. This is a neutral value as ALCLS would need 4.88 years to pay back of all of its debts.

With an excellent Debt to FCF ratio value of 4.88, ALCLS belongs to the best of the industry, outperforming 83.58% of the companies in the same industry.

A Debt/Equity ratio of 0.65 indicates that ALCLS is somewhat dependend on debt financing.

ALCLS has a Debt to Equity ratio (0.65) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.65
Debt/FCF	4.88
Altman-Z	-0.8

ROIC/WACCN/A

WACC6.17%

2.3 Liquidity

ALCLS has a Current Ratio of 1.73. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.73, ALCLS perfoms like the industry average, outperforming 44.78% of the companies in the same industry.

A Quick Ratio of 1.73 indicates that ALCLS should not have too much problems paying its short term obligations.

ALCLS has a Quick ratio (1.73) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.73
Quick Ratio	1.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALCLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.54%, which is quite impressive.

The Revenue has grown by 357.43% in the past year. This is a very strong growth!

Measured over the past years, ALCLS shows a quite strong growth in Revenue. The Revenue has been growing by 16.44% on average per year.

EPS 1Y (TTM)45.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-325%

Revenue 1Y (TTM)357.43%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%85.12%

3.2 Future

The Earnings Per Share is expected to decrease by -75.28% on average over the next years. This is quite bad

Based on estimates for the next years, ALCLS will show a very strong growth in Revenue. The Revenue will grow by 30.02% on average per year.

EPS Next Y-235.09%

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

EPS Next 5YN/A

Revenue Next Year63.01%

Revenue Next 2Y30.93%

Revenue Next 3Y12.51%

Revenue Next 5Y30.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALCLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALCLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALCLS indicates a rather cheap valuation: ALCLS is cheaper than 89.55% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	13.7
EV/EBITDA	N/A

4.3 Compensation for Growth

ALCLS's earnings are expected to decrease with -75.28% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALCLS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTIS

EPA:ALCLS (7/25/2025, 7:00:00 PM)

2.23

+0.33 (+17.49%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-12 2025-05-12/amc

Earnings (Next)07-31 2025-07-31

Inst Owners18.59%

Inst Owner ChangeN/A

Ins Owners2.82%

Ins Owner ChangeN/A

Market Cap223.73M

Analysts84.62

Price Target6.63 (197.31%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)82%

Min EPS beat(2)18.3%

Max EPS beat(2)145.69%

EPS beat(4)4

Avg EPS beat(4)73.41%

Min EPS beat(4)6.42%

Max EPS beat(4)145.69%

EPS beat(8)6

Avg EPS beat(8)27.22%

EPS beat(12)9

Avg EPS beat(12)23.55%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)108.7%

Min Revenue beat(2)55.84%

Max Revenue beat(2)161.56%

Revenue beat(4)4

Avg Revenue beat(4)91.56%

Min Revenue beat(4)50.31%

Max Revenue beat(4)161.56%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.56
P/FCF	13.7
P/OCF	11.41
P/B	2
P/tB	2.02
EV/EBITDA	N/A

EPS(TTM)-0.52

EYN/A

EPS(NY)-0.75

Fwd EYN/A

FCF(TTM)0.16

FCFY7.3%

OCF(TTM)0.2

OCFY8.76%

SpS0.63

BVpS1.11

TBVpS1.1

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.12%
ROE	-41.34%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	4.64%
FCFM	25.96%

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score7

Asset Turnover0.19

Health

		Industry Rank	Sector Rank
Debt/Equity	0.65
Debt/FCF	4.88
Debt/EBITDA	N/A
Cap/Depr	19.36%
Cap/Sales	5.21%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.73
Quick Ratio	1.73
Altman-Z	-0.8

F-Score7

WACC6.17%

ROIC/WACCN/A

Cap/Depr(3y)12.8%

Cap/Depr(5y)139.39%

Cap/Sales(3y)9.66%

Cap/Sales(5y)33.81%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)45.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-325%

EPS Next Y-235.09%

EPS Next 2Y-58.04%

EPS Next 3Y-75.28%

EPS Next 5YN/A

Revenue 1Y (TTM)357.43%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%85.12%

Revenue Next Year63.01%

Revenue Next 2Y30.93%

Revenue Next 3Y12.51%

Revenue Next 5Y30.02%

EBIT growth 1Y35.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-28.14%

EBIT Next 3Y-33.24%

EBIT Next 5Y-29.24%

FCF growth 1Y174.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y192.9%

OCF growth 3YN/A

OCF growth 5YN/A

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens